Clinical trials: Recurrent NSCLC
Advanced Solid Tumor, Non-small Cell Lung Cancer
Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1
This will be a Phase 1 Open-label, dose escalation and expansion study of MT-6402 (an Engineered Toxin Body (ETB)) in subjects with advanced solid cancer that expresses PD-L1
- Conditions
- Advanced Solid Tumor, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck
- Trial name
- NCT04795713
- Testing
- MT-6402
- Where
- 16 sites in United States
- Volunteers
- 64 people
- Sponsor
- Molecular Templates, Inc.
Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
This phase II trial studies how well osimertinib works in treating patients with non-small cell lung cancer with EGFR exon 20 insertion mutation that is stage IIIB-IV or has come back after a period of improvement (recurrent).
- Conditions
- Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7
- Trial name
- NCT03191149
- Testing
- Biospecimen Collection, Computed Tomography with Contrast, Echocardiography Test
- Where
- 347 sites in United States
- Volunteers
- 46 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumor, Adult, Colorectal Cancer
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
The goal of this study is to test A2B395, an allogeneic logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), non-small cell lung cancer (NSCLC), head and neck squamous cell…
- Conditions
- Solid Tumor, Adult, Colorectal Cancer, Non-Small Cell Lung, NSCLC (Non-small Cell Lung Cancer)
- Trial name
- DENALI-1 (NCT06682793)
- Testing
- A2B395, xT CDx with HLA-LOH assay
- Where
- 10 sites in United States
- Volunteers
- 240 people
- Sponsor
- A2 Biotherapeutics Inc.
Anxiety Disorder, Recurrent Non-small Cell Lung Cancer
Cognitive Behavioral Therapy in Treating Anxiety in Patients With Stage IV Non-Small Cell Lung Cancer and Their Caregivers
This pilot clinical trial studies cognitive behavioral therapy in treating anxiety in patients with stage IV non-small cell lung cancer and their caregivers.
- Conditions
- Anxiety Disorder, Recurrent Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Trial name
- NCT01729689
- Testing
- counseling intervention, questionnaire administration, quality-of-life assessment
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Stanford University
Non-small Cell Lung Cancer
BPI-7711 Capsule in Patients With EGFR Mutation T790M Positive Non-small Cell Lung Cancer
Lung cancer has the highest incidence rate in China and is also a very common cancer in the world. BPI-7711 is a new drug developed for patients with non-small cell lung cancer.
- Trial name
- NCT03386955
- Testing
- BPI-7711 Capsule
- Where
- 4 sites in China
- Volunteers
- 215 people
- Sponsor
- Beta Pharma Shanghai
Lung Cancer
PF-00299804 in Stage IIIB or Stage IV Non-Small Cell Lung Cancer Not Responding to Standard Therapy for Advanced or Metastatic Cancer
RATIONALE: PF-00299804 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether PF-00299804 is more effective than a placebo in treating patients with advanced…
- Trial name
- NCT01000025
- Testing
- PF-00299804
- Where
- 89 sites in United States, Argentina and 10 more
- Volunteers
- 720 people
- Sponsor
- NCIC Clinical Trials Group
Non-Small Cell Lung Cancer
A Study Comparing Bevacizumab Therapy With or Without Erlotinib for First-Line Treatment of Non-Small Cell Lung Cancer (ATLAS)
This is a Phase IIIb, multicenter, randomized, placebo-controlled trial to evaluate the safety and efficacy of chemotherapy+bevacizumab followed by bevacizumab+erlotinib versus bevacizumab+erlotinib placebo in subjects with…
- Trial name
- NCT00257608
- Testing
- bevacizumab, erlotinib HCl
- Where
- 247 sites in United States, Argentina and 15 more
- Volunteers
- 1,145 people
- Sponsor
- Genentech, Inc.
Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Bortezomib in Treating Patients With Advanced Non-small Cell Lung Cancer
Phase II trial to study the effectiveness of bortezomib in treating patients who have stage IIIB, stage IV, or recurrent non-small cell lung cancer.
- Conditions
- Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Trial name
- NCT00040768
- Testing
- bortezomib
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
NSCLC
RGL-270 + ICI in Advanced NSCLC
This is a single-center, open-label, investigator-initiated clinical trial. It aims to evaluate the safety and tolerability of RGL-270 in combination with a PD-1/PD-L1 inhibitor, to assess immunogenicity, preliminary efficacy…
- Trial name
- NCT07652125
- Testing
- RGL-270 in Combination with PD-1/PD-L1 Inhibitors, Physician's Choice SOC
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Guangdong Association of Clinical Trials
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity
Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer
This randomized phase I/II trial studies the side effects, best way to give, and best dose of erlotinib and bevacizumab when given with cetuximab and how well giving erlotinib and cetuximab together with or without bevacizumab…
- Conditions
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Basal Cell Carcinoma of the Lip, Recurrent Colon Cancer
- Trial name
- NCT00101348
- Testing
- erlotinib hydrochloride, cetuximab, bevacizumab
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- National Cancer Institute (NCI)
Non-small Cell Lung Cancer
Special Drug Use-results Surveillance of Tabrecta Tablets
This study was an uncontrolled, primary data collection-based observational study to be conducted as a central registration system, multicenter special drug-use results surveillance.
- Trial name
- NCT04575025
- Testing
- Tabrecta tablets
- Where
- 78 sites in Japan
- Volunteers
- 109 people
- Sponsor
- Novartis Pharmaceuticals
Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Suramin, Paclitaxel, and Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
Phase II trial to study the effectiveness of combining suramin, paclitaxel, and carboplatin in treating patients who have stage IIIB or stage IV non-small cell lung cancer.
- Conditions
- Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Trial name
- NCT00006929
- Testing
- suramin, carboplatin, paclitaxel
- Where
- United States
- Volunteers
- 82 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Colorectal Cancer
Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors
RATIONALE: Bortezomib may stop the growth of solid tumors by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Conditions
- Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Kidney Cancer
- Trial name
- NCT00620295
- Testing
- bortezomib, gemcitabine hydrochloride
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Brain Neoplasms, Carcinoma, Non-Small-Cell Lung
Study of Neurologic Progression With Motexafin Gadolinium and Radiation Therapy (SMART)
The primary purpose of the study is to determine if patients with brain metastases from non-small cell lung cancer treated with Motexafin Gadolinium and whole brain radiation therapy retain their neurologic function and ability…
- Conditions
- Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Metastases, Neoplasm
- Trial name
- NCT00054795
- Testing
- Motexafin Gadolinium
- Where
- 92 sites in United States, Australia and 6 more
- Volunteers
- 550 people
- Sponsor
- Pharmacyclics LLC.
Cancer
OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer
RATIONALE: Studying protein expression in sentinel lymph node tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer.
- Trial name
- NCT00900302
- Testing
- protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 98 people
- Sponsor
- OHSU Knight Cancer Institute
Lung Cancer
Celecoxib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Celecoxib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It may also stimulate the immune system in different ways and stop tumor cells from growing.
- Trial name
- NCT00104767
- Testing
- celecoxib
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma
PBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer
This phase I trial studies the side effects and best dose of PBF-1129 in combination with nivolumab in treating patients with non-small cell lung cancer that has come back (recurrent) or spread to other places in the body…
- Conditions
- Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8
- Trial name
- NCT05234307
- Testing
- Adenosine A2B Receptor Antagonist PBF-1129, Biospecimen Collection, Nivolumab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Dwight Owen
Non-small Cell Lung Cancer, Minimal Residual Disease
Liquid Biopsy-Based Novel Modality for Postoperative Management of Lung Cancer
The goal of this study is to develop new techniques for minimal residual disease(MRD) monitoring and to confirm the efficacy and safety of MRD-guided postoperative management for early stage non-small cell lung cancer.
- Conditions
- Non-small Cell Lung Cancer, Minimal Residual Disease, Adaptive Treatment
- Trial name
- NCT06930807
- Testing
- Adaptive postoperative management based on minimal residual disease
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Peking University People's Hospital
Lung Cancer, Metastatic Cancer
Dexamethasone and Supportive Care With or Without Whole-Brain Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer That Has Spread to the Brain and Cannot Be Removed By Surgery
RATIONALE: Steroid therapy, such as dexamethasone, may reduce swelling, pain, and other symptoms of inflammation and may be effective in treating some of the problems caused by cancer and cancer treatment.
- Trial name
- NCT00403065
- Testing
- dexamethasone, quality-of-life assessment, radiation therapy
- Where
- 70 sites in United Kingdom
- Volunteers
- 1,000 people
- Sponsor
- Medical Research Council
Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma
Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer
This phase II trial compares cabozantinib alone and the combination of cabozantinib and nivolumab to standard chemotherapy in the treatment of patients with non-squamous non-small cell lung cancer (NSCLC).
- Conditions
- Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
- Trial name
- NCT04310007
- Testing
- Biospecimen Collection, Cabozantinib S-malate, Computed Tomography
- Where
- 611 sites in United States
- Volunteers
- 117 people
- Sponsor
- National Cancer Institute (NCI)